The 11 MedTech companies participating in cLAB Ventures Global Mentorship Programme
cLAB Ventures has launched its mentorship programme on the 3rd of August to accelerate the business development of startups innovating in the field of oncology. The London-based company aims to counterbalance the negative effects of the global pandemic, as COVID-19 took a toll on cancer research projects by limiting laboratory capacities, changing the communication channels, and the way of life.
The acceleration programme lasts for 4 months, from August to November. The Mentorship Programme includes 7 in-depth learning sessions held by business, finance, and MedTech experts, 1-on-1 mentoring, networking, and a pitching opportunity.
The workshops and mentoring sessions run virtually throughout the programme, the teams can learn more about fundraising, marketing, and sales planning, resource management, and growth opportunities. The learning and mentoring sessions help the cohort prepare for the closing event which gives an insight into the oncology innovation ecosystem and puts the startups in front of international investors.
Due to the international nature of the program, it has gained great popularity and visibility from the beginning. The participating startups come from 9, the mentors from 12 different countries.
The 2020 cohort
Antegenes is a biotechnology and healthcare company developing and implementing innovative genetic tests. They have developed genetics-based risk assessment tests for four cancer types (breast prostate colorectal cancer and melanoma genetic risk tests) based on polygenic risk score (PRS) technology. The tests assess patients’ personal cancer risks and include clinical recommendations for further treatment and selection of health behaviours.
BrachyDOSE offers a tool that enables oncologists to provide more accurate and successful treatments in high dose brachytherapy procedures for breast, cervical, and prostate cancer patients. The device measures radiation dosing during brachytherapy procedures to provide data directly to the treatment planning software; this technology aims to reduce under- or over-dosing.
Canostix aims to beat cancer simply by diagnosing it as soon as possible so it can be treated in an early stage. They achieve this by developing a blood-based early detection test that combines vibrational spectroscopy and machine learning.
MicroX Labs HomeCyte
HomeCyte is building a home-care solution for cancer patients to monitor the side effects of chemotherapy at home by measuring platelets for internal bleeding and WBCs for infection monitoring. The solution works analogously to a glucose finger prick cartridge and the test enables immunocompromised patients to stay at home and recover while the real-time data are sent to the physician who, therefore, can monitor chemotherapy easily.
My Personal Therapeutics
My Personal Therapeutics offers personalised cancer therapeutics utilising technology developed at Mt Sinai Medical Center. They identify treatments for patients based on their tumor genetics. For each patient, we build a genetically matched fruit fly model of the tumor which is used for large-scale drug screening to find new and effective drug combinations.
OaCP produces and sells chemical reagents that improve the efficiency of the DNA reaction for cancer diagnostic tests. Their products are CE-IVD and patented in the EU, US, China, and India and are already in the market. Labs, hospitals, and R&D centers are their main customers, in particular centers that are using in situ hybridization technologies.
OncoChain creates a research platform based on a database with real-world data about oncological patients to generate useful analytics that can orientate research and deliver value-based care for providers. OncoChain develops two apps: OncoChain EHR, which provides data-driven, personalized, and effective recommendations for oncological care, and OncoChain Analytics, a tool for pharmaceutical companies and CROs.
Pear Bio uses organ-on-a-chip and computer vision technology to recreate visualize and compute tumor microenvironment-driven mechanisms of cancer spread and drug resistance. This allows us to compare drug performance side-by-side on patient tumor samples and eliminate ineffective treatment options before patients get them.
Remissio is a Berlin-based start-up that uses artificial intelligence to develop combination therapy for cancer, using artificial intelligence. They are the first company that used AI to model the adverse effects of immunotherapies in cancer patients using their deep understanding of gene and protein networks. Their software platform is designed to predict the right combination of chemo- and immunotherapy for cancer patients and develop new therapeutic combinations.
RUBY Nanomed is a spin-off from the International Nanotechnology Laboratory (INL) that aims to bring to the market the RUBYchip™: a device (microfluidic-based cartridge) that isolates, enumerates, and phenotypes circulating tumor cells (CTCs) directly from whole blood samples. RUBY Nanomed’s vision is to develop a POC instrument oncologists can use for real-time monitoring of the metastasis evolution during treatment, a tool that enables the prediction of disease evolution and drug resistance.
Thermy is a medical device with an A.I. software that analyses thermal images searching for abnormal temperatures related to tumor-growth, providing risk assessment for a potential breast cancer which is later validated by a medical doctor. Then the physicaian advises the patient about the following steps in the breast cancer diagnostic protocol, to have a Mammography/Ultrasound or to go directly to a confirmatory biopsy.
For investment opportunities, get in touch with our CEO, Sara at email@example.comLAB Ventures - August 18, 2020